Calton & Associates’s Medifast MED Stock Holding History

Calton & Associates’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-351	Closed	-$25K	–	904
2017 Q4	$25K	Buy	+351	New	+$23.3K	0.01%	849

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Calton & Associates's MED Position: Q1 2018 in Review

Calton & Associates sold out of Medifast (MED) in Q1 2018, closing a stake of 351 shares — an estimated $25K sold.

Calton & Associates first reported a position in MED in Q4 2017 and held it in 1 quarter. The position peaked at $25K in Q4 2017. 225 funds tracked by Wall St. Rank hold MED as of Q1 2018.

Calton & Associates reported no remaining Medifast position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 351 Medifast shares in Q1 2018, an estimated $25K.
Calton & Associates first reported a position in Medifast in Q4 2017 and held it in 1 quarter.
Calton & Associates's Medifast position peaked at $25K in Q4 2017.
225 funds tracked by Wall St. Rank held Medifast as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.